Pharma Industry Looks to Biomarker Programs to Predict Clinical Failure and Success: A New CHA Report Examines Emerging Applications in Biomarker Technology
Posted on: Monday, 13 June 2005, 12:00 CDT
WALTHAM, Mass., June 13 /PRNewswire/ -- The cost to discover and develop new drugs is escalating dramatically, while the number of approved new drug products is on the decline. Drug manufacturers, desperate for ways to expedite the drug discovery process while decreasing the expense, are turning to biomarkers as one possible solution. Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D is a new CHA Advances Report that examines the current state of biomarker development and application, with a close look at the technologies and how they are being deployed from research to the clinic.
Biomarkers can be influential in every phase of drug development, from drug discovery and preclinical evaluations through each phase of clinical trials and into post-marketing studies. Biomarkers can predict a patient's response to a compound, act as a surrogate endpoint, and aid in making efficacious and cost-saving decisions or in terminating candidates earlier in the research process. Patient enrichment strategies use biomarkers to identify patients who are more likely to respond to drug therapy or who are less likely to be susceptible to adverse events. This shift toward "personalized medicine," in which the patient receives a treatment based on their genetic as well as medical profile, is helping the drug industry to achieve the goal of cost-effective and faster health outcomes.
Michael T. Stocum, Managing Director, Personalized Medicine Partners LLC, is one of several experts interviewed for the CHA report. He addresses the question of when biomarkers will impact clinical development decision-making. "The answer is we're there today. It's happening in a lot of programs now, in several companies. If you ask...when will biomarkers enable delivery of personalized medicine approaches, I think we are still three to five years away from seeing significant numbers of examples."
For more information about Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D visit http://www.advancesreports.com/, or contact Cindy Ohlman at cohlman@chadvisors.com or 781-547-0202.
CHA Advances Reports are written by expert authors who collaborate with CHA to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.
Cambridge Healthtech Advisors
CONTACT: Cindy Ohlman of Cambridge Healthtech Advisors, +1-781-547-0202,cohlman@chadvisors.com
Web site: http://www.chadvisors.com/http://www.advancesreports.com/
Source: PRNewswire
Related Articles
- Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
- Workshop Tackles Challenges In Biomarker And Drug Development
- Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
- Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
- New Report Asks: 'Can the Use of Biomarkers As Surrogate End Points Stimulate the Drug-Development Lull?'
- OREXIGEN(TM) Therapeutics to Present CONTRAVE(TM) Clinical Summary at CBI's 3rd Annual Obesity Drug Development Summit
- Idera Pharmaceuticals Announces Formation of Oncology Clinical Advisory Board; Accomplished Physicians and Scientists in Cancer Drug Development
- New Approaches to Assessing Drug Safety Will Help Reduce Development Time and Costs, According to Industry Panel Convened By the Tufts Center for the Study of Drug Development
- Oncology Drug Development Update - Monotherapy Phase I Clinical Trials
- CHA Releases Findings of Inaugural Survey of Drug Development Activities in Emerging Regions By Western Biopharmaceutical Companies
 |
 |
User Comments (0)
RSS Feeds